| Giaconda | |
|---|---|
| Type | |
| Founded | 2004 |
| Founder | Thomas Borody |
| Headquarters | Sydney, Australia |
| Key people | Patrick McLean (CEO) |
| Website | http://www.giacondalimited.com/ |
Giaconda is an Australian biotechnology company headquartered in Sydney. "MMIV" redirects here For the Modest Mouse album see " Baron von Bullshit Rides Again " An entrepreneur is a person who has possession over a company enterprise, or Venture, and assumes significant accountability for the inherent risks and the outcome Thomas Borody is an Australian gastoenterologist based in Sydney who is noted for his work in novel therapies for gastrointestinal disorders Sydney (ˈsɪdniː is the most populous city in Australia, with a Metropolitan area population of approximately 4 For a topic outline on this subject see List of basic Australia topics. A website (alternatively web site or Web site, a back-construction from the Proper noun World Wide Web) is a collection of Web pages Biotechnology is Technology based on Biology, especially when used in Agriculture, Food science, and Medicine. Sydney (ˈsɪdniː is the most populous city in Australia, with a Metropolitan area population of approximately 4 The company was founded in 2004 to commercialise a number of drug combinations developed by Professor Thomas Borody, a Sydney-based gastroenterologist. Thomas Borody is an Australian gastoenterologist based in Sydney who is noted for his work in novel therapies for gastrointestinal disorders
Contents |
History
Giaconda was named after the Giaconda Vineyard and Winery, which is located nine kilometres southwest of Beechworth in the northeastern part of the Australian state of Victoria. Beechworth is a well-preserved historical town located in the north-east of Victoria Australia, famous for its major growth during the gold rush days of the mid-1850s That vineyard in turn derives its name from La Gioconda, which is a nickname for the Mona Lisa of Leonardo da Vinci. Mona Lisa (also known as La Gioconda) is a 16th century portrait painted in oil on a Poplar panel by Leonardo di ser Piero da Vinci ( April 15 1452 – May 2 1519 was an Italian Polymath, having been a scientist Mathematician, Engineer Giaconda uses a stylised version of the Mona Lisa in its company logo.
Giaconda's CEO is Mr Patrick McLean, a Canadian who was previously Senior Vice President European Commercial Operations of the Montreal-based Axcan Pharma. Montreal, or Montréal in French ( pronounced in French, in English) is the largest city in the Canadian province of Quebec Axcan Pharma Inc ( is a Mont-Saint-Hilaire Quebec based leading specialty pharmaceutical company that develops manufactures markets and distributes a broad line of Giaconda is a public company whose stock is traded on the Australian Stock Exchange under the stock code GIA. The Australian Securities Exchange ( ASX) is the primary Stock exchange in Australia. The company completed an Initial Public Offering in September 2005, issuing 12 million shares at 50 Australian cents each. Initial public offering (IPO, also referred to simply as a "public offering" is when a company issues Common stock or shares to the public for the first Thomas Borody currently owns around 70% of the stock.
Products
Giaconda is working on five products, all of which have been given names ending in '-conda'.
Myoconda, the company's lead product, is a combination of the antibiotics rifabutin, clarithromycin and clofazimine. In modern usage an antibiotic is a Chemotherapeutic agent with activity against Microorganisms such as Bacteria, fungi or Protozoa Rifabutin is a Bactericidal Antibiotic drug primarily used in the treatment of Tuberculosis. Clarithromycin is a Macrolide Antibiotic used to treat Pharyngitis, Tonsillitis, acute maxillary Sinusitis, acute bacterial exacerbation Clofazimine is a fat-soluble riminophenazine dye used in combination with Rifampicin and Dapsone as multidrug therapy (MDT for the treatment of Leprosy The combination is envisaged as a new treatment for Crohn's Disease. Crohn's disease is a Disease of the Digestive system which may affect any part of the Gastrointestinal tract from Mouth to Anus Myoconda was first devised by Thomas Borody around 1997[1]. The product has its origins in Borody's view that Crohn's disease is caused by infection with the bacterium Mycobacterium avium paratuberculosis, and that the disease can therefore be fought using drugs effective against the bacterium, such as those used in Myoconda. Mycobacterium avium subspecies paratuberculosis is an obligate Pathogenic bacteria in the Genus Mycobacteria. In 2000 Borody's organisation granted Pharmacia an option to license the Myoconda patent in return for that company agreeing to conduct a Phase III clinical trial. Pharmacia was a Pharmaceutical company in Sweden. History Pharmacia was founded in 1911 in Stockholm, Sweden In health care clinical trials are conducted to allow safety and Efficacy data to be collected for new drugs or devices The results of a Phase II trial were published in 2002[2]. In health care clinical trials are conducted to allow safety and Efficacy data to be collected for new drugs or devices The Phase III trial in 213 Crohn's patients was completed in September 2004 was results announced in 2005, however by this stage Pharmacia had merged with Pfizer and the latter company had decided not to exercise its Myoconda option. Pfizer Incorporated ( is a major Pharmaceutical company, which ranks number one in the world in sales A non-binding letter of intent was signed in April 2006 with Forest Laboratories for the UK and Irish market. Forest Laboratories is a pharmaceutical company headquartered in New York City USA A second Phase III trial is planned, and Giaconda hopes to be able to launch the product in the United States in 2008.
Hepaconda is a product for the treatment of Hepatitis C infection. Hepatitis C is a blood-borne infectious disease that is caused by the Hepatitis C virus ( HCV) affecting the Liver. The product, a combination of bezafibrate with chenodeoxycholic acid, was invented in 2001[3]. Bezafibrate (Bezalip and various other brand names is a Fibrate Drug used for the treatment of Hyperlipidaemia. Chenodeoxycholic acid (also known as chenodesoxycholic acid) is a Bile acid. Hepaconda is being developed as a 'rescue therapy' for Hepatitis C patients that have exhausted other treatment options. It is also envisaged that Hepaconda could be used to treat Primary Biliary Cirrhosis and Non-alcoholic steatohepatitis. Primary biliary cirrhosis is an Autoimmune disease of the Liver marked by the slow progressive destruction of the small bile ducts ( Bile canaliculi) within Non-alcoholic fatty liver disease ( NAFLD) is fatty inflammation of the Liver when this is not due to excessive alcohol use Giaconda had initially envisaged using Ursodeoxycholic acid as the bile acid in Hepaconda, but in 2006 the company shifted its attention to the use of chenodeoxycholic acid, having decided that its patent protection extended to all bile acid / fibrate combinations other than bezafibrate plus ursodoxycholic acid. Ursodiol, also known as ursodeoxycholic acid and the Abbreviation UDCA, is one of the secondary Bile acids which are metabolic byproducts
Heliconda, a product for the treatment of drug-resistant Helicobacter pylori, is a combination of the antibiotics rifabutin and amoxicillin and the proton pump inhibitor drug pantoprazole. Helicobacter pylori ( is a Gram-negative, microaerophilic Bacterium that inhabits various areas of the stomach and Duodenum. Rifabutin is a Bactericidal Antibiotic drug primarily used in the treatment of Tuberculosis. Amoxicillin ( INN) or amoxycillin ( BAN) is a moderate-spectrum bacteriolytic β-lactam antibiotic used to treat Bacterial Infections Proton pump inhibitors (or "PPI"s are a group of drugs whose main action is pronounced and long-lasting reduction of Gastric acid production Pantoprazole (brand names Pantopan in Italy Protium; Protonix; Pantozol; Pantor; Pantoloc; Astropan; Controloc Heliconda was invented in 1998[4]. In 2006 the results of a Phase II study of Heliconda in around 130 patients with resistant H. pylori infection was published. This study demonstrated an eradication of the infection in 90. 9% of patients treated with Heliconda[5].
Ibaconda is a product for the treatment of Constipation-predominant Irritable Bowel Syndrome. In Gastroenterology, irritable bowel syndrome ( IBS) is a Functional bowel disorder characterized by mild to severe Abdominal pain, discomfort The product, invented by Thomas Borody in 1997[6], is a combination of the anti-inflammatory drug olsalazine and the anti-gout drug colchicine. Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Gout (also called metabolic arthritis) is a disease created by a buildup of Uric acid. Colchicine is a highly poisonous Natural product and Secondary metabolite, originally extracted from plants of the genus Colchicum ( Autumn
Picoconda is a bowel preparation for use in gastrointestinal tract procedures. This product was invented by Thomas Borody in 1995[7]. It represents an attempt to replace conventional bowel preparations, which are often considered unpalatable. The product contains a laxative called sodium picosulphate, but capsulised and mixed with electrolytes so that it is palatable. Laxatives (or purgatives) are foods compounds or drugs taken to induce bowel movements or to loosen the stool most often taken to treat Constipation.
References
- ^ WO patent application 9843667
- ^ Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure? (June 26, 2006). Events 363 - Roman Emperor Julian is killed during the retreat from the Sassanid Empire. Year 2006 ( MMVI) was a Common year starting on Sunday of the Gregorian calendar. Retrieved on 2006-06-06. Year 2006 ( MMVI) was a Common year starting on Sunday of the Gregorian calendar. Events 1508 - Maximilian I Holy Roman Emperor, is defeated in Friulia by Venetian forces; he is forced to sign a three-year
- ^ WO patent application 0180852
- ^ WO patent application 9956749 - US Patent 6,489,317 was granted in 2002
- ^ Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. (June 26, 2006). Events 363 - Roman Emperor Julian is killed during the retreat from the Sassanid Empire. Year 2006 ( MMVI) was a Common year starting on Sunday of the Gregorian calendar. Retrieved on 2006-06-06. Year 2006 ( MMVI) was a Common year starting on Sunday of the Gregorian calendar. Events 1508 - Maximilian I Holy Roman Emperor, is defeated in Friulia by Venetian forces; he is forced to sign a three-year
- ^ WO patent application 9850043 - US Patent 6,426,338 was granted in 2002
- ^ US patent 5858403, granted in 1999
External links
Dapyx Software network: MP3 Explorer | Ebook Manager | Zenithic